Sacituzumab + cisplatin for uterine neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Sep 2023: Trial registered, NCT06040970
  2. 28 Oct 2024: Trial started, NCT06040970

The trials

NCT06040970: Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

State
Under way
Phase
Phase 1 and Phase 2
People
54 planned
Started
28 Oct 2024
Primary completion
1 Jul 2031
Arms
Ovarian cancer Cohort, Endometrial cancer Cohort
Results
None posted
  1. 18 Sep 2023: Trial registered
  2. 28 Oct 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.